Background {#Sec1}
==========

The *RAS* oncogene plays a fundamental role in human tumorigenesis \[[@CR1]\]. Activating mutations in its three proto-oncogenes---*HRAS*, *KRAS* and *NRAS*---are found in nearly all human cancers. Thyroid cancer is one of the earliest cases where activating *RAS* mutations were discovered \[[@CR2]\]. Today, the role of *RAS* oncogene in thyroid tumorigenesis has been well established \[[@CR3]--[@CR5]\]. Mutations in *RAS* genes occur, on average, in 30--45 % follicular thyroid cancer (FTC), 30--45 % follicular variant papillary thyroid cancer (FVPTC), 20--40 % poorly differentiated thyroid cancer (PDTC), 10--20 % anaplastic thyroid cancer, and rarely classical papillary thyroid cancer (PTC). *RAS* mutations also occur in 20--25 % benign follicular thyroid adenoma (FTA). Considerable interest has been drawn to the potential clinical utility of *RAS* mutations as diagnostic and prognostic molecular markers, among other molecular markers, for thyroid cancer \[[@CR6]\]. Given these occurrence patterns in thyroid tumors, however, *RAS* mutations themselves have low diagnostic sensitivities and specificities. Also, the role of *RAS* mutations in the clinical behavior of thyroid tumor is uncertain. Consequently, the clinical picture of *RAS* mutations in thyroid cancer has been a blurred one.

*RAS* mutations as diagnostic molecular markers for thyroid nodules {#Sec2}
-------------------------------------------------------------------

Clinical management of thyroid cancer usually starts with the evaluation of thyroid nodules, which is extremely common, with a prevalence of 50--70 % on ultrasonography \[[@CR7], [@CR8]\]. The diagnostic mainstay of thyroid nodules is fine needle aspiration biopsy (FNAB). In the last decade, much effort has been made to apply *RAS* mutations as diagnostic molecular markers to FNAB of thyroid nodules, particularly those with indeterminate cytology, which currently represents a major diagnostic challenge in clinical practice. Indeterminate thyroid cytology includes three categories---atypia of undetermined significance (AUS), follicular neoplasm (FN) and suspicious for malignancy \[[@CR9]\]. Surgical treatment for thyroid nodules cytologically suspicious for malignancy is generally accepted because of its high preoperative malignancy probability (around 60--70 %) and the treatment decision seems to be relatively easy to make. How to treat AUS and FN, which have a moderate risk of malignancy (10--30 %), is a more challenging dilemma in treatment decision making. Resolution of this dilemma is believed to rely on the development of effective diagnostic molecular marker-based tests \[[@CR6]\]. An ideal diagnostic molecular marker should have a 100 % or near-100 % sensitivity and specificity. Yet, *RAS* mutations have been proven to have inferior sensitivities and specificities for thyroid cancer. An effective strategy to apply *RAS* mutations to the diagnosis of thyroid cancer is their combinational use with other molecular markers, particularly genetic markers \[[@CR6]\]. A prominent example is the panel of genetic makers, including *RAS* mutations, *BRAF* V600E mutation, *RET/PTC* and *PAX8/PPAR*γ rearrangements, which, in a single-center unblinded study, yielded increased diagnostic sensitivities for thyroid cancer in the indeterminate cytological setting to 88 % for AUS and 87 % for FN \[[@CR10]\]. The sensitivity of this test on overall non-selected thyroid cytology was still high at 80 %, albeit lower, in a double-blinded multicenter study \[[@CR11]\]. The recently discovered *TERT* promoter mutations \[[@CR12]\] were shown to be diagnostically applicable to FNAB \[[@CR13]\]. Expansion of the genetic diagnostic panel to include additional genetic markers, including *TERT* promoter mutations, has resulted in an improved sensitivity for the FN category to 90 %, bringing the negative predictive value to 96 % \[[@CR14]\]. Indeterminate thyroid cytology consists mostly of follicular thyroid tumors and the malignant types are mainly FTC and FVPTC, which most commonly harbor *RAS* mutations. Therefore, *RAS* mutations are an important component that helps make the genetic panel diagnostically sensitive, propelling for high negative predictive values. It is expected that as the diagnostic efficiency of the genetic panel containing *RAS* mutations is confirmed and further improved, ideally through large blinded multicenter optimizing studies, it will become possible to use such a genetic panel to help reliably rule out malignancy for thyroid nodules.

*RAS* mutations in cytologically benign thyroid nodules {#Sec3}
-------------------------------------------------------

Since FTA is a main thyroid tumor in the indeterminate cytology category and *RAS* mutations occur commonly in FTA, albeit less frequently than FTC and FVPTC, use of the diagnostic genetic panel is expected to result in a large number of *RAS* mutation-positive but cytologically benign or indeterminate thyroid nodules. How to appropriately manage these nodules has been unclear. Because of the preferential occurrence of *RAS* mutations in malignant over benign thyroid tumors and the established oncogenic functions of *RAS* mutations in human tumorigenesis, there is reasonable concern about the prognosis of cytologically benign or indeterminate thyroid nodules harboring *RAS* mutations. Consequently, some physicians may recommend surgical treatment for all *RAS* mutation-positive thyroid nodules. Others, on the other hand, may argue for non-surgical management and conservative follow-up for *RAS* mutation-positive but cytologically benign thyroid nodules, since non-surgical management of cytologically benign thyroid nodules is currently the standard management \[[@CR15]\]. This confusion is a result of the lack of knowledge of the clinical behavior of such nodules in the long run.

The picture now becomes clearer with light shed by a marvelous recent study from Medici et al. of the Alexander group \[[@CR16]\]. In this study, the authors investigated the diagnostic value of *RAS* mutations on FNAB for thyroid cancer and the clinical behavior of *RAS* mutation-positive thyroid tumors. As expected, the authors confirmed the low diagnostic sensitivity and specificity of *RAS* mutations when used alone. An important novel finding, however, is that a group of *RAS* mutation-positive but cytologically benign thyroid nodules that were available for non-surgical management and conservative monitoring all showed excellent stability without radiographic growth or adverse clinical consequences after a long-term clinical follow-up (mean 8.3 years). This provides the first evidence that *RAS* mutation-positive but cytologically benign thyroid nodules behave as true benign nodules and can be conservatively managed for long term. Given the expected rising number of such patients in the coming years, long-term non-surgical management of such nodules would likely have many benefits, such as cost savings, avoidance of potential surgical complications and preservation of the thyroid function. It should be noted, though, that the prognosis of *RAS*-positive but cytologically benign thyroid nodules in an even longer term beyond the follow-up time in the Medici et al. study remains unknown. Further studies with longer follow-up durations are needed to provide an even clearer picture. Also, the clinical significance of *RAS* mutations in AUS/FN nodules remains unclear.

Benign clinical prognosis of benign thyroid nodules {#Sec4}
---------------------------------------------------

Consistent with the limited role of *RAS* mutations in benign thyroid nodules discussed above, a recent publication in *BMC Medicine* by Medici et al., demonstrated the safety of long-term conservative clinical follow-up of cytologically benign thyroid nodules \[[@CR17]\]. It has not been established how long benign thyroid nodules can be safely and conservatively followed clinically. Repeat evaluation of benign thyroid nodules at 1--2 years or even shorter intervals is currently common practice. This practice, however, has no direct evidence to support. In 1,254 patients with 1,819 cytologically benign thyroid nodules, with a median time of 1.4 years to first follow-up (ranging 0.5--14.1 years), the authors found no difference in malignancy or mortality between various follow-up intervals. Even though after three years of follow-up, some benign thyroid nodules could grow and even cause compressive symptoms requiring thyroidectomy in certain cases, the authors did not identify a difference in risk of malignancy. The results support the authors' recommendation that the interval of repeat evaluation can be safely extended to three years, reducing the unnecessary visits and medical interventions. This will likely have a profound impact on the healthcare saving, given the large number of patients with benign thyroid nodules. These findings by Medici et al. are consistent with a recent Italian study similarly showing a generally long-term stability and benign prognosis of benign thyroid nodules \[[@CR18]\]. These clinical findings also again support the notion that *RAS* mutation alone plays a limited role in the transformation of benign thyroid nodules as many of such nodules expectedly harbor *RAS* mutations \[[@CR4]\].

*RAS* mutations as prognostic molecular markers for thyroid cancer {#Sec5}
------------------------------------------------------------------

Another important finding in the earlier Medici et al. study \[[@CR16]\] is that, even when histologically confirmed to be malignant, the *RAS* mutation-positive tumors have limited aggressiveness; these are usually FVPTC without aggressive tumor behavior, such as extrathyroidal extension, lymph node metastasis and distant metastasis. These tumors are highly curable and have an excellent prognosis. This is in contrast to *BRAF* V600E mutation \[[@CR19]--[@CR21]\] or *TERT* promoter mutations \[[@CR12], [@CR13], [@CR22], [@CR23]\], which are associated with aggressiveness and poor clinical outcomes of thyroid cancer. Medici et al. confirmed the association of the *BRAF* V600E mutation with aggressive behavior of thyroid cancer in their study \[[@CR16]\]. These results are consistent with the previous findings that, compared with the *BRAF* V600E mutation, *RAS* mutations were associated with better differentiation of thyroid cancer as reflected by normal or near-normal expression of thyroid iodide-handling genes in contrast to the considerable down-regulation of these genes with *BRAF* mutation \[[@CR4], [@CR24], [@CR25]\]. Some studies showed an association between poor tumor behavior and *RAS* mutations in FTC \[[@CR26]\] and PDTC \[[@CR27], [@CR28]\]. This likely reflects the coexistence of *RAS* mutations with additional oncogenic alterations, such as *TERT* promoter mutations; *RAS* mutations and *TERT* promoter mutations are significantly associated with each other in thyroid cancer \[[@CR29]\] and coexistence of the two types of mutations was shown to be associated with a significantly higher tumor recurrence compared with *RAS* mutation alone in FTC \[[@CR30]\], similar to the coexistence of *BRAF* V600E mutation with *TERT* promoter mutations that is associated with sharply increased aggressive clinicopathological behavior, tumor recurrence and patient mortality in PTC \[[@CR23], [@CR31]\]. *RAS* mutation alone is most likely associated with limited aggressiveness of thyroid cancer. This concept is in fact supported by a mouse model in which *Kras* mutation alone caused only benign thyroid neoplasia and its coexistence with *Pten* deletion in the PI3K pathway caused transformation of the tumor into FTC with metastasis \[[@CR32]\].

One advantage of the expanded diagnostic genetic panel is that it tests not only *RAS* mutations, but also other important oncogenic genetic changes, including *TERT* promoter mutations. Therefore, coexistence of *RAS* mutations with additional oncogenic changes can be identified using such a genetic panel; the result should then be treated differently than finding *RAS* mutation alone in terms of prognostic significance. If only *RAS* mutations are found in differentiated thyroid cancer, it is reasonable and safe to assume a good prognosis.

Conclusions {#Sec6}
===========

Studies in recent years together with the studies by Medici et al. \[[@CR16], [@CR17]\] have shed bright light on the role of *RAS* mutations in the clinical behavior of thyroid tumors and their value in assisting the management of thyroid nodules and thyroid cancer, making a previously blurred clinical picture now emerging clearer. Overall, cytologically benign thyroid nodules, even when harboring *RAS* mutations, have an excellent prognosis and can be safely and conservatively followed at relatively long time intervals; differentiated thyroid cancer, when harboring *RAS* mutations alone without other coexisting genetic alterations, generally lacks aggressive behaviors. Given this advancement in understanding *RAS* mutations, the following recommendations on their clinical use as diagnostic and prognostic molecular markers may be considered: 1) *RAS* mutations have an important diagnostic value as a component of a genetic marker panel that has high negative predictive values and can thus help diagnostically rule out thyroid malignancy; 2) *RAS* mutation-positive but cytologically benign thyroid nodules can be non-surgically managed and followed for long term; 3) *RAS* mutation-positive differentiated thyroid cancer has an excellent prognosis and can be treated with less aggressive measures, e.g. hemithyroidectomy, in the appropriate clinical settings; and 4) unless clinically indicated otherwise, *RAS* mutation-positive AUS or FN thyroid nodules may be treated with hemithyroidectomy and, if shown to be benign on additional molecular tests, such as gene expression classifier \[[@CR33]\], may be considered to be non-surgically managed and conservatively followed. These uses of *RAS* mutations as molecular markers are applicable only when *RAS* mutation alone exists; if coexisting oncogenic genetic alterations are also found, such as *TERT* promoter mutations or mutations in the PI3K pathway, the tumor should be treated more aggressively in appropriate clinical settings.
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